Anzeige
Meldung des Tages: Goldchance mit Substanz: Warum dieses Projekt Investoren aufhorchen lässt

Tuhura Biosciences Aktie News

Aktie
WKN:  A3EWMJ ISIN:  US8989201038 US-Symbol:  HURA Branche:  Biotechnologie Land:  USA
0,364 €
-0,008 €
-2,15%
08:04:13 Uhr
Depot/Watchlist
Marktkapitalisierung *
1,07 Mio. €
Streubesitz
51,94%
KGV
-5,37
Index-Zuordnung
-

Tuhura Biosciences News

02.02.26 - PR Newswire
TuHURA Biosciences received FDA Orphan Drug Designation for IFx-2.0 for the Treatment of Stage IIB to Stage IV Cutaneous Melanoma
TuHURA Biosciences received FDA Orphan Drug Designation for IFx-2.0 for the Treatment of Stage IIB to Stage IV Cutaneous Melanoma PR Newswire
15.12.25 - PR Newswire
TuHURA Biosciences Announces its Release of Kintara's Contingent Value Right (CVR) as Kintara's REM-001 Meets Primary Safety Endpoint Achieving Contractual Milestone
TuHURA Biosciences Announces its Release of Kintara's Contingent Value Right (CVR) as Kintara's REM-001 Meets Primary Safety Endpoint Achieving Contractual Milestone PR ...
11.12.25 - PR Newswire
TuHURA Biosciences Provides Corporate Update Following Recent Financing
TuHURA Biosciences Provides Corporate Update Following Recent Financing PR Newswire
08.12.25 - PR Newswire
TuHURA Biosciences Presents Data Demonstrating the Delta Opioid Receptor (DOR) as a New Target in Overcoming Acquired Resistance to Immune Checkpoint Inhibitors at the 57th ASH Annual Meeting and Exposition
TuHURA Biosciences Presents Data Demonstrating the Delta Opioid Receptor (DOR) as a New Target in Overcoming Acquired Resistance to Immune Checkpoint Inhibitors at the ...
14.11.25 - PR Newswire
TuHURA Biosciences, Inc. Reports Third Quarter 2025 Financial Results and Provides a Corporate Update
TuHURA Biosciences, Inc. Reports Third Quarter 2025 Financial Results and Provides a Corporate Update PR Newswire
03.11.25 - PR Newswire
TuHURA Biosciences Discovery Research on Targeting the Delta Opioid Receptor (DOR) to Reprogram Myeloid-Derived Suppressor Cells (MDSCs) Selected for Oral Presentation at the 67th ASH Annual Meeting and Exposition
TuHURA Biosciences Discovery Research on Targeting the Delta Opioid Receptor (DOR) to Reprogram Myeloid-​Derived Suppressor Cells (MDSCs) Selected for Oral Presentation ...
20.08.25 - PR Newswire
TuHURA Biosciences, Inc. to Present at the 27th Annual H.C. Wainwright Global Investment Conference
TuHURA Biosciences, Inc. to Present at the 27th Annual H.C. Wainwright Global Investment Conference PR Newswire
14.08.25 - PR Newswire
TuHURA Biosciences, Inc. Reports Second Quarter 2025 Financial Results and Provides a Corporate Update
TuHURA Biosciences, Inc. Reports Second Quarter 2025 Financial Results and Provides a Corporate Update PR Newswire
01.07.25 - PR Newswire
TuHURA Biosciences, Inc. Announces Inclusion in the Russell 3000® and Russell 2000® Indexes
TuHURA Biosciences, Inc. Announces Inclusion in the Russell 3000® and Russell 2000® Indexes PR Newswire
30.06.25 - PR Newswire
TuHURA Biosciences Completes Acquisition of Kineta
TuHURA Biosciences Completes Acquisition of Kineta PR Newswire
24.06.25 - PR Newswire
TuHURA Biosciences Initiates Its Phase 3 Accelerated Approval Trial of IFx-2.0 as an Adjunctive Therapy to Keytruda® (pembrolizumab) in First Line Treatment for Advanced or Metastatic Merkel Cell Carcinoma
TuHURA Biosciences Initiates Its Phase 3 Accelerated Approval Trial of IFx-2.0 as an Adjunctive Therapy to Keytruda® (pembrolizumab) in First Line Treatment for Advanced or ...
23.06.25 - PR Newswire
TuHURA Biosciences, Inc. and Kineta, Inc. Stockholders Approve Proposed Merger and All Related Proposals
TuHURA Biosciences, Inc. and Kineta, Inc. Stockholders Approve Proposed Merger and All Related Proposals PR Newswire
09.06.25 - PR Newswire
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates HURA and VIGL on Behalf of Shareholders
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates HURA and VIGL on Behalf of Shareholders PR Newswire
09.06.25 - PR Newswire
FDA Removes Partial Clinical Hold on TuHURA Biosciences' Phase 3 Accelerated Approval Trial for IFx-2.0 in Advanced or Metastatic Merkel Cell Carcinoma
FDA Removes Partial Clinical Hold on TuHURA Biosciences' Phase 3 Accelerated Approval Trial for IFx-2.0 in Advanced or Metastatic Merkel Cell Carcinoma PR Newswire
03.06.25 - PR Newswire
TuHURA Biosciences, Inc. Enters into $12.5 Million Equity Financing Transaction and Receives Additional $3.0 Million in Warrant Exercise Proceeds to Advance Its Pipeline of Novel Treatments to Overcome Primary Resistance to Cancer Immunotherapy
TuHURA Biosciences, Inc. Enters into $12.5 Million Equity Financing Transaction and Receives Additional $3.0 Million in Warrant Exercise Proceeds to Advance Its Pipeline of Novel ...
02.06.25 - PR Newswire
TuHURA Biosciences Presents IFx-Hu2.0 Trial-in-Progress Poster at the 2025 American Society of Clinical Oncology Annual Meeting
TuHURA Biosciences Presents IFx-Hu2.0 Trial-​in-Progress Poster at the 2025 American Society of Clinical Oncology Annual Meeting PR Newswire
15.05.25 - PR Newswire
TuHURA Biosciences, Inc. Reports First Quarter 2025 Financial Results and Provides a Corporate Update
TuHURA Biosciences, Inc. Reports First Quarter 2025 Financial Results and Provides a Corporate Update PR Newswire
13.05.25 - PR Newswire
TuHURA Biosciences, Inc. to Present at the 3rd Annual H.C. Wainwright BioConnect Conference
TuHURA Biosciences, Inc. to Present at the 3rd Annual H.C. Wainwright BioConnect Conference PR Newswire
05.05.25 - PR Newswire
TuHURA Biosciences, Inc. Initiates Phase 1b/2a Study of IFx-Hu2.0 as an Adjunctive Therapy to Keytruda® (pembrolizumab) in First Line Treatment for Metastatic Merkel Cell Carcinoma of Unknown Primary Origin (MCCUP)
TuHURA Biosciences, Inc. Initiates Phase 1b/2a Study of IFx-Hu2.0 as an Adjunctive Therapy to Keytruda® (pembrolizumab) in First Line Treatment for Metastatic Merkel Cell ...
28.04.25 - PR Newswire
TuHURA Biosciences and Kineta Present Updated Results from Kineta's Phase I-II Study of KVA12123 and TuHURA's Mechanism of IFx-Hu2.0 Responses After Anti-PD-1 Therapy Failure in Advanced Melanoma at the American Association for Cancer Research Annual Meeting
TuHURA Biosciences and Kineta Present Updated Results from Kineta's Phase I-II Study of KVA12123 and TuHURA's Mechanism of IFx-Hu2.0 Responses After Anti-PD-1 Therapy ...

Newssuche

Videos

newspaper
03.02.26
2026 02 03 17 34 Trendjumper Einführung
Zunächst inormieren wir unsere Stammkunden bezüglich des bevorstehenden Seminars und bieten für ... Mehr »